Here's Why AnaptysBio Stock Fell on Tuesday
Shares of AnaptysBio (NASDAQ: ANAB), a clinical-stage biopharmaceutical company, tumbled 10.3% today. Investors weren't impressed by top-line data for ANB019, the company's second most advanced new drug candidate.
AnaptysBio announced top-line data from an interim analysis of the ongoing phase 2 study with ANB019 known as Gallop. The Gallop trial is supposed to enroll up to 10 patients with a rare autoimmune disorder called generalized pustular psoriasis (GPP). But one of the first three patients treated dropped out early, following a serious adverse event that could have been caused by ANB019.
Image source: Getty Images.
Source Fool.com
